Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Cantor Fitzgerald
Chinese Patent Office
Chubb
Federal Trade Commission

Generated: September 18, 2019

DrugPatentWatch Database Preview

AZILECT Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

When do Azilect patents expire, and what generic alternatives are available?

Azilect is a drug marketed by Teva and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in AZILECT is rasagiline mesylate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.

Drug patent expirations by year for AZILECT
Pharmacology for AZILECT
Synonyms for AZILECT
(+)-AGN-1135
(1R)-2,3-Dihydro-N-2-propyn-1-yl-1H-inden-1-amine Mesylate
(1R)-2,3-Dihydro-N-2-propynl-1H-inden-1-amine methanesulfonate
(1R)-N-(2-propynyl)-2,3-dihydro-1H-inden-1-amine methanesulfonate
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; methanesulfonic acid
(R)-2,3-Dihydro-N-2-propynyl-1-indenamine Mesylate
(R)-N-(Prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine methanesulfonate
(R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine methanesulfonate
(R)-N-2-Propynyl-1-indanamine methanesulfonate
161735-79-1
1H-Inden-1-amine, 2,3-dihydro-N-2-propyn-1-yl-, (1R)-, methanesulfonate (1:1)
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (R)-, methanesulfonate
735R791
AB0011313
AB2000506
AC-724
AC1MHJZQ
ACT06733
Agilect
AK-60119
AKOS005145768
AN-6874
ANW-52542
AX8150251
Azilect (TN)
BC213842
BG0559
BS-1009
CAS-161735-79-1
CC-34228
CHEMBL1201142
CS-2458
CTK8B6102
D02562
DSSTox_CID_27826
DSSTox_GSID_47848
DSSTox_RID_82589
DTXSID8047848
EN300-123038
FT-0631191
HY-14605
I09-0543
JDBJJCWRXSVHOQ-UTONKHPSSA-N
KB-81371
KS-00000H13
LH8C2JI290
LS-186552
MCULE-3183761977
methanesulfonic acid; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
methanesulfonic acid; (1R)-N-prop-2-ynylindan-1-amine
methanesulfonic acid;(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
MFCD08460604
MolPort-005-937-324
N-Propargyl-1(R)-aminoindan methanesulfonate
NCGC00168774-01
NCGC00168774-02
Q-101873
Rasagiline (mesylate)
Rasagiline mesilate
Rasagiline mesilate (JAN)
Rasagiline mesylate
Rasagiline mesylate (USAN)
Rasagiline mesylate [USAN]
Rasagiline mesylate, >=98% (HPLC)
Rasagiline methanesulfonate
RL02071
s2102
SC-08804
SCHEMBL158439
ST24049117
TC-064138
Tox21_112635
Tox21_112635_1
TV 1012
TV-1030
TVP 1012
TVP-1012
UNII-LH8C2JI290
Z1820079046

US Patents and Regulatory Information for AZILECT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 AB RX Yes No   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 AB RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 AB RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for AZILECT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006   Try a Free Trial   Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006   Try a Free Trial   Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for AZILECT
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe   Try a Free Trial

Supplementary Protection Certificates for AZILECT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0812190 05C0033 France   Try a Free Trial PRODUCT NAME: RASAGILINE; NAT. REGISTRATION NO/DATE: EU/1/04/304/001-007 20050221; FIRST REGISTRATION: EU/1/4/304/001-007 20050221
0812190 C300205 Netherlands   Try a Free Trial PRODUCT NAME: RASAGILINE, DESGEWENST IN DE VORM VAN EENFARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/04/304/001 T/M 007 20050221
0812190 31/2005 Austria   Try a Free Trial PRODUCT NAME: RASAGILINE; REGISTRATION NO/DATE: EU/1/04/304/001-007 20050221
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Daiichi Sankyo
Julphar
Deloitte
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.